• Nebivolol Hydrochloride in Precision β1-Adrenergic Pathwa...

  2025-09-28

  Discover how Nebivolol hydrochloride, a highly selective β1-adrenoceptor antagonist, is revolutionizing β1-adrenergic receptor signaling research and cardiovascular pharmacology. This article uniquely explores its mechanistic specificity, negative findings in mTOR inhibition, and advanced applications in dissecting adrenergic signaling pathways.

• MG-132 in Precision Proteostasis: From Ubiquitin-Proteaso...

  2025-09-27

  Explore the advanced role of MG-132, a cell-permeable proteasome inhibitor peptide aldehyde, in orchestrating precise ubiquitin-proteasome system inhibition and targeted autophagy modulation. This article uniquely integrates cutting-edge research and practical insights for apoptosis assay, cell cycle arrest studies, and therapeutic innovation.

• Adenosine Triphosphate (ATP) as a Systems-Level Regulator...

  2025-09-26

  Discover how Adenosine Triphosphate (ATP) orchestrates cellular metabolism beyond energy transfer, acting as a systems-level regulator of mitochondrial proteostasis and enzyme turnover. This article offers a unique, in-depth analysis connecting ATP’s biochemical properties to advanced research applications, with new insights into metabolic pathway investigation.

• ARCA Cy5 EGFP mRNA (5-moUTP): Integrating Fluorescent mRN...

  2025-09-25

  Discover how ARCA Cy5 EGFP mRNA (5-moUTP) revolutionizes mRNA delivery system research by combining advanced fluorescent labeling with 5-methoxyuridine modification to suppress innate immune activation. This article uniquely explores the mechanistic interplay between translation efficiency, localization, and immunogenicity in mammalian cells.

• Bufuralol Hydrochloride: Unraveling β-Adrenergic Blockade...

  2025-09-24

  Explore Bufuralol hydrochloride as a non-selective β-adrenergic receptor antagonist in advanced cardiovascular pharmacology research. This article uniquely dissects its dual role in membrane stabilization and human-relevant pharmacokinetics, bridging molecular action and next-generation disease modeling.

• Annexin V as a Quantitative Probe for Early Apoptosis and...

  2025-09-23

  Explore the application of Annexin V as an apoptosis detection reagent in quantitative assays, shedding light on its role in phosphatidylserine externalization and immune cell fate. This article highlights Annexin V’s unique utility in dissecting immune dysregulation in cancer and neurodegenerative models.

• L-660711 Another issue is that the vast

  2025-03-03

  

  Another issue is that the vast majority of data from PET and CSF are from selected participants recruited through tertiary care dementia centers [176]. It is widely recognized that clinic-based participants differ from community-based studies, for example, the amount, type, and distribution of neuro

• Targeted disruption of the Akt gene

  2025-03-03

  

  Targeted disruption of the Akt1 gene in mice induces a growth retardation phenotype [4,19]. Akt2 KO mice reveal mild growth retardation and insulin resistance [4,20,21]. Akt1/2 double KO (DKO) mice display severe growth deficiency and die shortly after birth. These mice exhibit impaired bone and ski

• The AHR potentially enhances IDO expression possibly via cro

  2025-03-03

  

  The AHR potentially enhances IDO-expression, possibly via crosstalk with several inflammatory signaling pathways (shown by now for IL6 and ‘signal transducer and activator of transcription’ (STAT) 3, and for NFκB, toll like receptor-pathways) [56,59,60]. IDO metabolizes Trp to kynurenines, which are

• To investigate further the clinical and

  2025-03-03

  

  To investigate further the clinical and mutational spectrum associated with -related dyskinesia, we here performed a screen in a large series of patients affected with an unexplained hyperkinetic movement disorder, resulting in the identification of 2 pediatric patients presenting with a novel pheno

• Some of the studies reported elevated ADA levels in schizoph

  2025-03-03

  

  Some of the studies reported elevated ADA levels in schizophrenia patients (SZ) undergoing treatment with antipsychotics (Dutra et al., 2010; Brunstein et al., 2007; Ghaleiha et al., 2011). However, it is unclear whether the increased serum ADA reported in these studies was the consequence of treatm

• The AAP s policy statement on childhood adversities is a

  2025-03-03

  

  The AAP’s policy statement on childhood adversities is a call to the pediatric UCM05 to apply the knowledge toward developmental screening in clinical practice. It is a movement to increase education around childhood adversity as a public health crisis and to build trauma-informed care into pediatr

• br Conclusions Triptans are HT B D F

  2025-03-03

  

  Conclusions Triptans are 5-HT1B/1D/(1F) receptors agonists and are considered as the gold standard for acute migraine treatment that have been proven effective. Unfortunately, they are contraindicated in patients with cardiovascular diseases due to their vasoconstrictor (side) effects (MaassenVan

• In conclusion AXL overexpression preexisted in a subgroup of

  2025-03-03

  

  In conclusion, AXL overexpression preexisted in a subgroup of treatment-naive lung adenocarcinoma specimens harboring an activating EGFR mutation or in those with wild-type EGFR. Anti-AXL therapeutics delivered up front in combination with the EGFR inhibitor might overcome intrinsic or acquired resi

• br Results br Discussion br Conclusion The flux of

  2025-03-01

  

  Results Discussion Conclusion The flux of glucose into cytosolic short chain acyl-CoAs was maintained in pure beta Trobalt in the presence of inhibition of ATP citrate lyase with hydroxycitrate and also in a cell line with >90% ATP citrate lyase knockdown suggesting that a pathway other th

16728 records 16/1116 page Previous Next First page 上5页 1617181920 下5页 Last page